RPRX Royalty Pharma plc - Class A
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY. The company has class B common shares outstanding that are privately held.
$37.62 +2.19 (6.18%)
As of 03/27/2023 14:25:37 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Large cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation: United Kingdom
IPO date: 12/31/1997
Outstanding shares: 443,166,030
Average volume: 2,484,707
Market cap: $15,422,177,844
Current dividend yield: 2.20%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: BMVP7Y0
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%